Why us?  Why us? please click dropdown
4.8/5 out of 3,500+ reviews
Regulated: CQC Registered | 1-5796078466
  • Verified Content: Approved by the Women’s Health Clinic Clinical Team.
  • Educational Use: This is not a substitute for professional medical advice, diagnosis, or treatment.
  • Clinical Assessment: Individual suitability is determined by a clinician; results may vary.
  • MEDICAL EMERGENCY:

    If you need urgent help, use NHS 111. For a life-threatening emergency, call 999.

 Author  Find more about the author
Dr Farzana Khan

Dr Farzana Khan

Verified

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013). Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She offers careful assessment, discusses medical and conservative options first, and considers selected regenerative or aesthetic treatments where appropriate. Dr Farzana also trains clinicians as a KOL/Trainer with Neauvia, Asclepion Laser, and RegenLab (since 2023). Ongoing CPD includes IMCAS, CCR, ACE and expert training in women’s intimate fillers, PRP, and polynucleotide injectables. Her approach is simple: clear explanations, realistic expectations, and shared decision-making. Authored and medically reviewed by Dr Farzana Khan.

MD MRCGP DFFP
Was this answer helpful?
Rate Dr Farzana's explanation
Dryness & GSM faq

How many visits should I plan for assessment and follow-up?

How many visits should I plan for assessment and follow-up? Most people with genitourinary syndrome of menopause (GSM) need 1 detailed assessment, a review at 6–12 weeks to gauge real-life change, and another at 3–6 months to fine-tune maintenance. If you add device-based care or injectables, expect 2–3 treatment sessions spaced 4–8 weeks apart with a review afterwards. Timings adapt to your goals and any red flags. Educational only. Results vary. Not a cure.

Clinical Context

Who may need fewer visits? People whose main limiter is vestibular sting and micro-tears who respond to a scheduled moisturiser, a generous silicone-based lubricant for the longest glide, and accurate placement of local oestrogen/DHEA. Many reach stable comfort after the assessment plus one 6–12 week review.

Who may need closer follow-up? Anyone with suspected infection (BV/thrush/UTI), contact dermatitis, or dermatoses (e.g., lichen sclerosus); those on anticoagulants considering injectables; or people with pronounced pelvic floor guarding after painful sex—physio/dilator coaching can be pivotal.

Next steps you can action now. Keep cleansing gentle (lukewarm water; bland emollient as a soap substitute), schedule moisturiser 2–4 nights weekly, match lubricant to your needs (water-based for condoms/versatility; silicone-based for tender vestibule; avoid oil with latex), and diary triggers and wins. Arrive at reviews ready to decide on the lowest effective maintenance.

Evidence-Based Approaches

Patient-friendly basics: The NHS provides plain-English guidance on causes, self-care and when to seek help for vaginal dryness, including moisturiser/lubricant principles.

Guideline framing (UK): The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life; these timelines underpin 6–12 week and 3–6 month reviews.

Product and prescribing detail: UK dosing/cautions for vaginal oestrogens and prasterone (DHEA) are set out in the British National Formulary (BNF), supporting long-term, lowest-effective maintenance once settled.

Effectiveness benchmarks: Systematic reviews in the Cochrane Library show that local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo—useful for setting expectations at 6–12 week reviews.

Pathophysiology & nuance: Peer-reviewed overviews indexed on PubMed describe GSM mechanisms (thinner epithelium, raised pH, fewer lactobacilli), explaining why phased reviews align with biological and mechanical change.